Under means testing proposal by the Bush administration higher-income Medicare beneficiaries would have to pay higher premiums and deductibles under the prescription drug benefit.
Ads by Google
Nearly $15 billion could have been saved this year if private insurers that offer Medicare prescription drug plans had administrative costs similar to those of Medicare and if they obtained discounts on drugs.
GlaxoSmithKline's HIV protease inhibitor LEXIVA may now be administered with 100mg of ritonavir, an agent that increases, or boosts, the level of protease inhibitors in the bloodstream.
Prescription drug makers are creating pay-for-performance contracts with European state-run health care systems.
A Minnesota law that limits gifts from pharmaceutical companies could lead to similar laws in other states.
Astellas Pharma announced results of an analysis showing that Vaprisol produced a prompt and sustained (over the 4-day treatment period) increase in serum sodium concentration.
FDA has granted clearance to expand the intended use for HemosIL D-Dimer HS to exclude venous thromboembolism in outpatients suspected of deep vein thrombosis and pulmonary embolism (PE).
Legislation to reauthorize the Prescription Drug User Fee Act delays the approval of new medications.
World Trade Organization to manufacture its fixed-dose combination antiretroviral drug Apo-triAvir for Rwanda.
Isis Pharmaceuticals announced the first safety results from its ongoing Phase 2 open-label extension (OLE) study of ISIS 301012 in patients with familial hypercholesterolemia.
The underlying principles of how to develop, market, sell and manage a blockbuster drug that will outperform the competition are still the same - and are still sought after by pharmaceutical and biotech companies alike.
Surface Logix announced the presentation of positive safety and efficacy data from its innovative Phase 1 repeat-dose clinical trial of its investigational drug candidate SLx-4090.
The standard Medicare Part B monthly premium will be $96.40 in 2008, an increase of $2.90, or 3.1 percent, from the $93.50 Part B premium for 2007.
If consumers stay put in their current Medicare prescription drug plans, the average beneficiary will see a 21% increase in their monthly premiums for 2008.
FDA is tightening the potency specifications for levothyroxine sodium, used to treat underactive thyroid glands and other thyroid conditions, to ensure the drug retains its potency over its entire shelf life.
FDAtoday announced the award of a two-year, $1.5 million contract to the Center for Professional Development (CPD) to assist with the transformation of FDA's Center for Drug Evaluation and Research.
Global pharmaceutical companies now can use country-specific information from Cegedim Strategic Data to gauge how patients suffering from similar ailments react to a multitude of treatment regimens.
Pennsylvanians Governor urged the General Assembly to promptly act on the unfinished components of his innovative "Prescription for Pennsylvania" health care reform initiative.
Sutter County launched a discount card program to help consumers cope with the high price of prescription drugs.
Rhode Island will delay a new Medicaid fee structure that will require about 14,000 Medicaid beneficiaries to contribute copayments for prescription drugs because of federal objections
A bill would establish reimbursement schedules and other guidelines for independent pharmacists working with insurers and pharmacy benefit managers.
Reps. Anna Eshoo (D-Calif.) and Mike Rogers (R-Mich.) on Thursday introduced a bill (HJ Res 54) that would reverse a CMS decision to limit Medicare coverage for use of anemia medications -- Aranesp, manufactured by Amgen, and Procrit, manufactured by Johnson & Johnson -- in cancer patients, CQ HealthBeat reports (CQ HealthBeat, 9/28).
USA Today examined a nationwide pilot program that seeks to show that more directly involving pharmacists with patients can improve care and lower the cost of treating patients with chronic illnesses.
Average premiums for stand-alone Medicare prescription drug plans will increase by 8.7% to $40 monthly in 2008.
Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for a 300mg tablet of the antiplatelet PLAVIX (clopidogrel bisulfate).